Innoviva (INVA) Income from Continuing Operations (2010 - 2026)
Innoviva (INVA) reported Income from Continuing Operations of 186563000.0 for Q1 2026, up 500.44% on a YoY basis from 31070824.82 in Q1 2025, and up 1449.66% quarter-over-quarter from 13823000.0 in Q4 2025.
Innoviva (INVA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Innoviva has reported Income from Continuing Operations for 17 years, with the latest figure at 186563000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 500.44% year-over-year to 186563000.0; the trailing twelve-month figure through Mar 2026 stood at 326345000.0 (up 460.2% YoY), and the FY2025 full-year result was 271363000.0, up 2424.54% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 186563000.0, up from 13823000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 229347000.0 in Q3 2022, with the low at 46589000.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 38951705.88 across 5 years, with a median of 21395000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 2757.85% — and 2025, when it soared 7312.78%.
- Innoviva's Income from Continuing Operations stood at 10328000.0 in 2022, then jumped by 36.31% to 6578000.0 in 2023, then sank by 60.22% to 10539000.0 in 2024, then plunged by 31.16% to 13823000.0 in 2025, then jumped by 1449.66% to 186563000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 186563000.0 (Q1 2026), 13823000.0 (Q4 2025), and 89917000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Innoviva | 1.65 Bn | 1.05 Bn | 75.83 Mn | 186.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186.56 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 89.92 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -34.69 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 82.05 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 34.87 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 229.35 Mn |
| Jun 30, 2022 | 21.40 Mn |
| Mar 31, 2022 | 37.86 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 102.68 Mn |
| Jun 30, 2021 | 110.88 Mn |